A Randomized Placebo Surgery Controlled Double-blinded Multi-center Phase 2 Clinical Trial Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease with Motor Fluctuations

The purpose of this study is to test the safety and efficacy of an experimental gene transfer therapy called VY-AADC02 in adult subjects with advanced Parkinson's Disease (PD). AADC is a naturally occurring protein found in the brain that converts levodopa (PD medication) to dopamine. The study product , delivered directly into the brain via a cannula with the imaging medium gadolinium, will increase production of AADC, which may increase dopamine levels. This in turn may provide improvement in PD symptoms. Please see pages 4-5 of the Protocol,"Study Rationale," for a more detailed discussion.

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: 99 years or below
• Gender: All